Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sawai Sets Out US Recalibration

Consolidating US Manufacturing Operations In Minnesota And Strengthening Portfolio

Executive Summary

Sawai Pharmaceutical has major plans for its US business that include consolidating its manufacturing operations at a single site and bolstering its pipeline and portfolio, Sawai president Kenzo Sawai tells Generics Bulletin in an exclusive interview.

You may also be interested in...



Sawai Focuses On New Products, Supply To 'Retain Trust' of Japan Generic Industry

Looking back at recent company decisions to shift product strategy, restructure its US Upsher-Smith business and acquire manufacturing sites from a former domestic competitor, Sawai's president shares the breadth of the Japanese firm’s vision.

Sawai Focuses On New Products, Supply To 'Retain Trust' of Japan Generic Industry

Looking back at recent company decisions to shift product strategy, restructure its US Upsher-Smith business and acquire manufacturing sites from a former domestic competitor, Sawai's president shares the breadth of the Japanese firm’s vision.

Sawai Maintains Strong Domestic Performance, Continues To Flounder In US

Sawai’s Q2 results mirrored those of Q1, with a strong performance in Japan but a weak one in the US. The firm is continuing to focus on establishing new production facilities in both territories.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel